SCHEMBL29772301

SCHEMBL29772301

COc1ccc(CNc2ncnc3c2c(C2CCCC2)cn3[C@@H]2O[C@H](COS(=O)(=O)c3ccc(C)cc3)[C@@H](O)[C@H]2O)c(OC)c1

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 7/20 0.46
▸ PRMT5 O14744 6/20 0.46
▸ ADORA1 P30542 2/20 0.41
▸ ADORA3 P0DMS8 2/20 0.41
▸ SLC29A1 Q99808 1/20 0.40
▸ RNMT O43148 1/20 0.39
▸ ADORA2A P29274 1/20 0.39
▸ UBA6 A0AVT1 1/20 0.39
▸ ATG7 O95352 1/20 0.39
▸ UBA7 P41226 1/20 0.39
▸ NAE1 Q13564 1/20 0.39
▸ UBA3 Q8TBC4 1/20 0.39
▸ SAE1 Q9UBE0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23273756 1.00 METTL3 (0.46) METTL3PRMT5ADORA1ADORA3SLC29A1
SCHEMBL29772282 0.89 RXFP1 (0.37) METTL3PRMT5ADORA1ADORA3ADORA2A
SCHEMBL29772268 0.84 PRMT5 (0.45) METTL3PRMT5ADORA1ADORA3ADORA2A
SCHEMBL23273841 0.84 PRMT5 (0.45) METTL3PRMT5ADORA1ADORA3ADORA2A
SCHEMBL29772256 0.79 PRMT5 (0.65) METTL3PRMT5
SCHEMBL23273897 0.79 PRMT5 (0.65) METTL3PRMT5
SCHEMBL23312996 0.77 ADORA3 (0.42) METTL3PRMT5ADORA1ADORA3ADORA2A
SCHEMBL29611607 0.74 ADORA1 (0.54) ADORA1ADORA3ADORA2A
SCHEMBL27090409 0.74 ADORA1 (0.54) ADORA1ADORA3ADORA2A
SCHEMBL23274005 0.74 METTL3 (0.46) METTL3PRMT5UBA6NAE1UBA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4048674-A2 METTL3 MODULATORS Accent Therapeutics, Inc. (US) 2022-08-31 — — EP disclosed
WO-2021079196-A9 METTL3 MODULATORS ACCENT THERAPEUTICS, INC (US) 2022-07-14 — — WO disclosed
Send feedback